Page 2

Mitokinin makes space for AbbVie
Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.
Corporates help eGenesis generate $125m
Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.
FogPharma finds $107m in series C
GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.
Olympus eyes Medi-Tate acquisition
Laborie is set to exit the medical device manufacturer after another of its investors, Olympus, announced its intention to pay $260m for its remaining shares.
Artizan crafts $11m series A2 round
Biohaven Therapeutics co-led Artizan Biosciences' latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.
Genomics gets its hands on $30m
The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.
Tenaya Therapeutics takes in $106m
GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.
Connect Bio to attach itself to public markets
Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.
Oxular eyes $37m round
Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.
Carisma charms its way to $59m
Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer's series B round, which already inlcuded Livzon, Merck & Co and AbbVie.

test reg